Previous close | 0.4000 |
Open | 0.4000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 70.00 |
Expiry date | 2024-10-18 |
Day's range | 0.4000 - 0.4000 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Key Insights Bio-Techne's estimated fair value is US$68.96 based on 2 Stage Free Cash Flow to Equity Current share...
Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, October 30, 2024, at 8:00 a.m. CDT to review its first quarter fiscal 2025 financial results.
ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady™, and LIfT BioSciences, ('LIfT' or 'the Company'), a rapidly emerging biotech company about to start clinical trials for its first-in-class allogeneic innate cell therapy, today announced that LIfT Biosciences has been awarded a $300,000 G-Rex® Grant to establish clinical manufacturing of its promising Neutrophil only Leukocyte Infusion Therapy (N-LIfT) platform.